EMBC — Embecta Corp.

Summary of Embecta Corp. Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $222 million, down 14.4% year-over-year (17.4% adjusted for constant currency).
• U.S. Revenue: Approximately $95 million, a decline of 29.4% (adjusted for constant currency).
• International Revenue: Approximately $126 million, a slight increase of 2.1% (down 4.1% adjusted for constant currency).
• Gross Profit: GAAP gross profit of $127.8 million (57.6% margin), down from $164.1 million (63.4% margin) year-over-year.
• Operating Income: GAAP operating income of $35 million (15.8% margin), down from $62.9 million (24.3% margin).
• Net Loss: GAAP net loss of $4.1 million ($0.07 loss per diluted share), compared to a net income of $23.5 million ($0.40 per diluted share) in the prior year.
• Adjusted Earnings: Adjusted net income of $16.1 million ($0.27 per diluted share), down from $40.7 million ($0.70 per diluted share) year-over-year.
• Free Cash Flow: Approximately $47 million generated in the first half of the year; $75 million in debt repaid.

2. Strategic Updates and Business Highlights

• Acquisition of Owen Mumford: Expected to close soon, contributing approximately $30 million in revenue for the fiscal year. This acquisition aims to diversify Embecta's product offerings beyond insulin delivery.
• Brand Transition: Over 75% of revenue now comes from products under the Embecta label, with substantial completion expected by the end of 2026.
• Product Development: Progress in developing market-appropriate syringes and pen needles, with regulatory submissions in process for new products.
• GLP-1 Strategy: Collaboration with over 30 pharmaceutical partners, with 40% in active negotiations or agreements. Launches of generic GLP-1 therapies co-packaged with Embecta's pen needles have begun in India and Canada.

3. Forward Guidance and Outlook

• Revised Revenue Guidance: Updated to a range of $1.015 billion to $1.035 billion, down from $1.071 billion to $1.093 billion.
• Adjusted Operating Margin Guidance: Reduced to 22.25% - 23.25% from 29% - 30%.
• Adjusted EPS Guidance: Lowered to $1.55 - $1.75 from $2.80 - $3.00.
• Debt Repayment Target: Continuing to aim for $150 million in debt repayment during 2026.
• Free Cash Flow Expectations: Now projected at $95 million - $105 million, down from $180 million - $200 million.

4. Bad News, Challenges, or Points of Concern

• U.S. Revenue Decline: Significant drop attributed to share loss in the pen needle category, particularly at a major customer, and overall market volume softness in insulin pens.
• Market Trends: Decline in insulin pen prescriptions, particularly in the retail channel, potentially influenced by the increasing affordability of GLP-1 drugs and the expiration of ACA subsidies.
• Inventory Reductions: Contributing to revenue declines, along with pricing pressures in the market.
• Operational Review: Initiated due to the magnitude of the revenue shortfall, indicating potential restructuring or cost-cutting measures.

5. Notable Q&A Insights

• Competitive Loss: The share loss at a major customer was deeper than anticipated, with implications for future pricing and contract negotiations.
• Market Dynamics: The decline in insulin pen prescriptions is attributed to a shift towards GLP-1 drugs and changes in purchasing patterns, with uncertainty about the duration of these trends.
• Long-term Growth: Management remains optimistic about returning to revenue growth, driven by the Owen Mumford acquisition and ongoing strategic initiatives in the B2B segment and product diversification.
• Trade Receivables: The factoring agreement for trade receivables remains intact and is standard practice, not affecting liquidity.

Overall, Embecta faces significant challenges in the near term, particularly in the U.S. market, but is pursuing strategic initiatives that could position the company for recovery and growth in the future.